Worldwide Consumer sales of $3.4 billion for the third quarter 2017 represented an increase of 2.9% versus the prior year, consisting of an operational increase of 1.6% and a positive impact from currency of 1.3%. Domestic sales decreased 0.5%, international sales increased 5.1%, which reflected an operational increase of 3.0% and a positive currency impact of 2.1%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 1.1%, domestic sales decreased 0.7% and international sales increased 2.3%.
Worldwide operational results, excluding the net impact of acquisitions and divestitures, were driven by over-the-counter products primarily Tylenol analgesic products and international smoking cessation aids as well as OGX and Neutrogena beauty products, partially offset by the negative impact of domestic baby care products, according to J&J.
The company increased its sales guidance for the full-year 2017 to a range of $76.1 billion to $76.5 billion.